PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Pharmacy Practice, Creighton University, Omaha, Nebraska, USA.\', \'Department of Clinical Research, Creighton University, Omaha, Nebraska, USA.\', \'Pharmacy Clinical Service, CHI Health, Omaha, Nebraska, USA.\', \'Risk Management Operations, CHI Health (Midwest), Omaha, Nebraska, USA.\', \'Medicine, Creighton University, Omaha, Nebraska, USA.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1002/phar.2613
?:doi
?:hasPublicationType
?:journal
  • Pharmacotherapy
is ?:pmid of
?:pmid
?:pmid
  • 34328670
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 1.28
?:rankingScore_hIndex
  • 97
is ?:relation_isRelatedTo_publication of
?:title
  • Bamlanivimab use in mild-to-moderate COVID-19 disease: A matched cohort design.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34328670>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34328670>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all